No Cover Image

Journal article 18 views 18 downloads

Recovery From COVID-19 in Multiple Sclerosis: A Prospective and Longitudinal Cohort Study of the United Kingdom Multiple Sclerosis Register

Afagh Garjani, Rod Middleton Orcid Logo, Richard Nicholas, Nikos Evangelou

Neurology - Neuroimmunology Neuroinflammation, Volume: 9, Issue: 1, Start page: e1118

Swansea University Author: Rod Middleton Orcid Logo

  • 59132.pdf

    PDF | Version of Record

    This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

    Download (366.52KB)

Abstract

To understand the course of recovery from coronavirus disease 2019 (COVID-19) among patients with multiple sclerosis (MS) and to determine its predictors, including patients' pre-COVID-19 physical and mental health status.<h4>Methods</h4>This prospective and longitudinal cohort stud...

Full description

Published in: Neurology - Neuroimmunology Neuroinflammation
ISSN: 2332-7812 2332-7812
Published: Ovid Technologies (Wolters Kluwer Health) 2022
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa59132
Tags: Add Tag
No Tags, Be the first to tag this record!
first_indexed 2022-01-10T15:30:05Z
last_indexed 2022-01-19T04:28:58Z
id cronfa59132
recordtype SURis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2022-01-18T16:15:09.0610328</datestamp><bib-version>v2</bib-version><id>59132</id><entry>2022-01-10</entry><title>Recovery From COVID-19 in Multiple Sclerosis: A Prospective and Longitudinal Cohort Study of the United Kingdom Multiple Sclerosis Register</title><swanseaauthors><author><sid>005518f819ef1a2a13fdf438529bdfcd</sid><ORCID>0000-0002-2130-4420</ORCID><firstname>Rod</firstname><surname>Middleton</surname><name>Rod Middleton</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2022-01-10</date><deptcode>HDAT</deptcode><abstract>To understand the course of recovery from coronavirus disease 2019 (COVID-19) among patients with multiple sclerosis (MS) and to determine its predictors, including patients' pre-COVID-19 physical and mental health status.&lt;h4&gt;Methods&lt;/h4&gt;This prospective and longitudinal cohort study recruited patients with MS who reported COVID-19 from March 17, 2020, to March 19, 2021, as part of the United Kingdom MS Register (UKMSR) COVID-19 study. Participants used online questionnaires to regularly update their COVID-19 symptoms, recovery status, and duration of symptoms for those who fully recovered. Questionnaires were date stamped for estimation of COVID-19 symptom duration for those who had not recovered at their last follow-up. The UKMSR holds demographic and up-to-date clinical data on participants as well as their web-based Expanded Disability Status Scale (web-EDSS) and Hospital Anxiety and Depression Scale (HADS) scores. The association between these factors and recovery from COVID-19 was assessed using multivariable Cox regression analysis.&lt;h4&gt;Results&lt;/h4&gt;Of the 7,977 patients with MS who participated in the UKMSR COVID-19 study, 599 reported COVID-19 and prospectively updated their recovery status. Twenty-eight hospitalized participants were excluded. At least 165 participants (29.7%) had long-standing COVID-19 symptoms for &#x2265;4 weeks and 69 (12.4%) for &#x2265;12 weeks. Participants with pre-COVID-19 web-EDSS scores &#x2265;7, participants with probable anxiety and/or depression (HADS scores &#x2265;11) before COVID-19 onset, and women were less likely to report recovery from COVID-19.&lt;h4&gt;Discussion&lt;/h4&gt;Patients with MS are affected by postacute sequelae of COVID-19. Preexisting severe neurologic impairment or mental health problems appear to increase this risk. These findings can have implications in tailoring their post-COVID-19 rehabilitation.</abstract><type>Journal Article</type><journal>Neurology - Neuroimmunology Neuroinflammation</journal><volume>9</volume><journalNumber>1</journalNumber><paginationStart>e1118</paginationStart><paginationEnd/><publisher>Ovid Technologies (Wolters Kluwer Health)</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint>2332-7812</issnPrint><issnElectronic>2332-7812</issnElectronic><keywords/><publishedDay>1</publishedDay><publishedMonth>1</publishedMonth><publishedYear>2022</publishedYear><publishedDate>2022-01-01</publishedDate><doi>10.1212/nxi.0000000000001118</doi><url/><notes/><college>COLLEGE NANME</college><department>Health Data Science</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>HDAT</DepartmentCode><institution>Swansea University</institution><apcterm/><funders>Multiple Sclerosis Society Grant: 131</funders><lastEdited>2022-01-18T16:15:09.0610328</lastEdited><Created>2022-01-10T15:27:02.3624568</Created><path><level id="1">Swansea University Medical School</level><level id="2">Medicine</level></path><authors><author><firstname>Afagh</firstname><surname>Garjani</surname><order>1</order></author><author><firstname>Rod</firstname><surname>Middleton</surname><orcid>0000-0002-2130-4420</orcid><order>2</order></author><author><firstname>Richard</firstname><surname>Nicholas</surname><order>3</order></author><author><firstname>Nikos</firstname><surname>Evangelou</surname><order>4</order></author></authors><documents><document><filename>59132__22097__b6423119082342529266004d4b7e6a59.pdf</filename><originalFilename>59132.pdf</originalFilename><uploaded>2022-01-10T15:29:10.6066441</uploaded><type>Output</type><contentLength>375319</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>http://creativecommons.org/licenses/by-nc-nd/4.0/</licence></document></documents><OutputDurs/></rfc1807>
spelling 2022-01-18T16:15:09.0610328 v2 59132 2022-01-10 Recovery From COVID-19 in Multiple Sclerosis: A Prospective and Longitudinal Cohort Study of the United Kingdom Multiple Sclerosis Register 005518f819ef1a2a13fdf438529bdfcd 0000-0002-2130-4420 Rod Middleton Rod Middleton true false 2022-01-10 HDAT To understand the course of recovery from coronavirus disease 2019 (COVID-19) among patients with multiple sclerosis (MS) and to determine its predictors, including patients' pre-COVID-19 physical and mental health status.<h4>Methods</h4>This prospective and longitudinal cohort study recruited patients with MS who reported COVID-19 from March 17, 2020, to March 19, 2021, as part of the United Kingdom MS Register (UKMSR) COVID-19 study. Participants used online questionnaires to regularly update their COVID-19 symptoms, recovery status, and duration of symptoms for those who fully recovered. Questionnaires were date stamped for estimation of COVID-19 symptom duration for those who had not recovered at their last follow-up. The UKMSR holds demographic and up-to-date clinical data on participants as well as their web-based Expanded Disability Status Scale (web-EDSS) and Hospital Anxiety and Depression Scale (HADS) scores. The association between these factors and recovery from COVID-19 was assessed using multivariable Cox regression analysis.<h4>Results</h4>Of the 7,977 patients with MS who participated in the UKMSR COVID-19 study, 599 reported COVID-19 and prospectively updated their recovery status. Twenty-eight hospitalized participants were excluded. At least 165 participants (29.7%) had long-standing COVID-19 symptoms for ≥4 weeks and 69 (12.4%) for ≥12 weeks. Participants with pre-COVID-19 web-EDSS scores ≥7, participants with probable anxiety and/or depression (HADS scores ≥11) before COVID-19 onset, and women were less likely to report recovery from COVID-19.<h4>Discussion</h4>Patients with MS are affected by postacute sequelae of COVID-19. Preexisting severe neurologic impairment or mental health problems appear to increase this risk. These findings can have implications in tailoring their post-COVID-19 rehabilitation. Journal Article Neurology - Neuroimmunology Neuroinflammation 9 1 e1118 Ovid Technologies (Wolters Kluwer Health) 2332-7812 2332-7812 1 1 2022 2022-01-01 10.1212/nxi.0000000000001118 COLLEGE NANME Health Data Science COLLEGE CODE HDAT Swansea University Multiple Sclerosis Society Grant: 131 2022-01-18T16:15:09.0610328 2022-01-10T15:27:02.3624568 Swansea University Medical School Medicine Afagh Garjani 1 Rod Middleton 0000-0002-2130-4420 2 Richard Nicholas 3 Nikos Evangelou 4 59132__22097__b6423119082342529266004d4b7e6a59.pdf 59132.pdf 2022-01-10T15:29:10.6066441 Output 375319 application/pdf Version of Record true This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. true eng http://creativecommons.org/licenses/by-nc-nd/4.0/
title Recovery From COVID-19 in Multiple Sclerosis: A Prospective and Longitudinal Cohort Study of the United Kingdom Multiple Sclerosis Register
spellingShingle Recovery From COVID-19 in Multiple Sclerosis: A Prospective and Longitudinal Cohort Study of the United Kingdom Multiple Sclerosis Register
Rod Middleton
title_short Recovery From COVID-19 in Multiple Sclerosis: A Prospective and Longitudinal Cohort Study of the United Kingdom Multiple Sclerosis Register
title_full Recovery From COVID-19 in Multiple Sclerosis: A Prospective and Longitudinal Cohort Study of the United Kingdom Multiple Sclerosis Register
title_fullStr Recovery From COVID-19 in Multiple Sclerosis: A Prospective and Longitudinal Cohort Study of the United Kingdom Multiple Sclerosis Register
title_full_unstemmed Recovery From COVID-19 in Multiple Sclerosis: A Prospective and Longitudinal Cohort Study of the United Kingdom Multiple Sclerosis Register
title_sort Recovery From COVID-19 in Multiple Sclerosis: A Prospective and Longitudinal Cohort Study of the United Kingdom Multiple Sclerosis Register
author_id_str_mv 005518f819ef1a2a13fdf438529bdfcd
author_id_fullname_str_mv 005518f819ef1a2a13fdf438529bdfcd_***_Rod Middleton
author Rod Middleton
author2 Afagh Garjani
Rod Middleton
Richard Nicholas
Nikos Evangelou
format Journal article
container_title Neurology - Neuroimmunology Neuroinflammation
container_volume 9
container_issue 1
container_start_page e1118
publishDate 2022
institution Swansea University
issn 2332-7812
2332-7812
doi_str_mv 10.1212/nxi.0000000000001118
publisher Ovid Technologies (Wolters Kluwer Health)
college_str Swansea University Medical School
hierarchytype
hierarchy_top_id swanseauniversitymedicalschool
hierarchy_top_title Swansea University Medical School
hierarchy_parent_id swanseauniversitymedicalschool
hierarchy_parent_title Swansea University Medical School
department_str Medicine{{{_:::_}}}Swansea University Medical School{{{_:::_}}}Medicine
document_store_str 1
active_str 0
description To understand the course of recovery from coronavirus disease 2019 (COVID-19) among patients with multiple sclerosis (MS) and to determine its predictors, including patients' pre-COVID-19 physical and mental health status.<h4>Methods</h4>This prospective and longitudinal cohort study recruited patients with MS who reported COVID-19 from March 17, 2020, to March 19, 2021, as part of the United Kingdom MS Register (UKMSR) COVID-19 study. Participants used online questionnaires to regularly update their COVID-19 symptoms, recovery status, and duration of symptoms for those who fully recovered. Questionnaires were date stamped for estimation of COVID-19 symptom duration for those who had not recovered at their last follow-up. The UKMSR holds demographic and up-to-date clinical data on participants as well as their web-based Expanded Disability Status Scale (web-EDSS) and Hospital Anxiety and Depression Scale (HADS) scores. The association between these factors and recovery from COVID-19 was assessed using multivariable Cox regression analysis.<h4>Results</h4>Of the 7,977 patients with MS who participated in the UKMSR COVID-19 study, 599 reported COVID-19 and prospectively updated their recovery status. Twenty-eight hospitalized participants were excluded. At least 165 participants (29.7%) had long-standing COVID-19 symptoms for ≥4 weeks and 69 (12.4%) for ≥12 weeks. Participants with pre-COVID-19 web-EDSS scores ≥7, participants with probable anxiety and/or depression (HADS scores ≥11) before COVID-19 onset, and women were less likely to report recovery from COVID-19.<h4>Discussion</h4>Patients with MS are affected by postacute sequelae of COVID-19. Preexisting severe neurologic impairment or mental health problems appear to increase this risk. These findings can have implications in tailoring their post-COVID-19 rehabilitation.
published_date 2022-01-01T04:16:12Z
_version_ 1737027981202685952
score 10.8793745